Outcome of special types of luminal breast cancer
Marco Colleoni(European Institute of Oncology), Giulia Viale(Vita-Salute San Raffaele University), Patrick Maisonneuve(European Institute of Oncology), Alberto Luini(Institute of Protein Biochemistry), A. Cardillo, Gino Perri, Emilia Montagna, Mauro G. Mastropasqua(University of Milan), Giuseppe Cancello, Giancarlo Pruneri(University of Milan), Nicole Rotmensz(European Organisation for Research and Treatment of Cancer), Mattia Intra, Paolo Veronesi, Monica Iorfida, Aron Goldhirsch(European Institute of Oncology), Massimiliano Mazza(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 123
Related Papers
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k